2,100
Participants
Start Date
March 1, 2021
Primary Completion Date
April 30, 2024
Study Completion Date
April 30, 2024
New test candidates
"The following new diagnostic tests will be done after the completion of the study with the samples (blood, sputum, urine) and data (digital X-ray) obtained during the study period:~CAD4TB / qXR Xpert Ultra® FLOW-TB TAM-TB 4RISK and COR Cepheid 3-gene signature cartridge BioMérieux ISIT TB blood transcription signature assay Multiplex LSHTM in-house host biomarker assay TB Screen biosignature SeroSelect~Retrospective testing of participants' samples and data acquired during the study period, differentiated between participants with co-prevalent/incipient TB and participants staying health throughout the trial"
Instituto Nacional de Saúde (INS) Centro de Investigação e Treino em Saúde da Polana Caniço, Maputo
NIMR - Mbeya Medical Research Centre, Mbeya
Biomedical Research & Training Institute (BRTI), Harare
European and Developing Countries Clinical Trials Partnership (EDCTP)
OTHER_GOV
Michael Hoelscher
OTHER